Fintel reports that on December 11, 2024, Jefferies upgraded their outlook for ICU Medical (NasdaqGS:ICUI) from Hold to Buy.

Jefferies upgraded ICU Medical (ICUI) to Buy from Hold with an unchanged price target of $200. The firm continues to like ICU’s core infusion ...

ICU Medical, Inc. develops, manufactures, and sells innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets ...

In a report released yesterday, Michael Toomey from Jefferies upgraded ICU Medical (ICUI – Research Report) to a Buy, with a price target of ...

For the partnership, medical device maker ICU will join its North American production and distribution expertise, along with its IV pumps and consumables know-how, with Otsuka’s IV solution and ...